Fractyl Health, Inc. Common Stock
NASDAQ:GUTSBiotechnology
-$0.01 today
- Market cap
- $55.18M
- Beta
- 2.34
- P/E (TTM)
- -0.6
- EPS (TTM)
- -$1.42
Volume 0.10M
Average 2.07M
Fair Value & DCF
Compare our fair value with your own assumptions
Intrinsic Alpha selects a valuation method suited to the business. Use the calculator below to build an independent scenario with your preferred cash-flow basis.
Fractyl Health, Inc. Common Stock
NASDAQ:GUTS
Intrinsic Alpha fair value
Locked
Current Price
$4.16
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Build your own valuation
Test an independent scenario and compare it with Intrinsic Alpha's estimate.
Sign in to use the DCF calculator
Free accounts get 5 valuations per week. Upgrade for more.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A1 analysts |
| Revenue | N/A | N/A | N/A | N/A2 analysts |
| Net Income | N/A | N/A | N/A | N/A2 analysts |
| EBIT | N/A | N/A | N/A | N/A2 analysts |
Analysis
Analysis will appear once historical growth or forward estimates are available for this company.
Estimates & History
Historical data and analyst estimates. Solid bars are actuals; dashed-border bars are future estimates.
Competitor Valuations
Peer stocks ranked by intrinsic value status
| Company | Market Cap | Price | Valuation | P/E | 1Y Return |
|---|---|---|---|---|---|
Artiva Biotherapeutics, Inc. NASDAQ:ARTV | $341.74M | $6.99 | Not rated | -2.7 | +20.82% |
ALX Oncology Holdings Inc. NASDAQ:ALXO | $176.28M | $1.31 | Not rated | -0.9 | -25.00% |
Sutro Biopharma, Inc. NASDAQ:STRO | $154.64M | $15.98 | Not rated | -0.0 | +2.95% |
Biomea Fusion, Inc. NASDAQ:BMEA | $95.44M | $1.32 | Not rated | -1.9 | -26.44% |
Precision BioSciences, Inc. NASDAQ:DTIL | $79.79M | $6.22 | Not rated | -1.9 | +38.76% |
aTyr Pharma, Inc. NASDAQ:ATYR | $29.91M | $0.31 | Not rated | -0.7 | -18.38% |
Continue the stock analysis
Jump to another research area for this company.